Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin III deficiency in ischaemic stroke.

V Hossmann, W D Heiss, H Bewermeyer

    Klinische Wochenschrift
    |June 15, 1983
    PubMed
    Summary

    Antithrombin III (AT III) activity is often reduced in acute ischemic stroke patients, indicating increased intravascular coagulation. Early AT III concentrate substitution may improve neurological outcomes in progressive cases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [CorBene: a new model for collaborative care of patients with congestive heart failure].

    Herz·2012
    Same author

    [Significance of health-related quality of life and religiosity for the acceptance of chronic pain].

    Schmerz (Berlin, Germany)·2008
    Same author

    Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate.

    Brain & development·2007
    Same author

    [Wound botulism in heroin addicts in Germany].

    Deutsche medizinische Wochenschrift (1946)·2006
    Same author

    MRI and ultrasonographic imaging of a patient with carotidynia.

    Cephalalgia : an international journal of headache·2006
    Same author

    [Clinical implications of meningococcal disease].

    Deutsche medizinische Wochenschrift (1946)·2006

    Area of Science:

    • Neurology
    • Hematology
    • Biochemistry

    Background:

    • Ischemic stroke is a leading cause of disability and mortality.
    • Antithrombin III (AT III) plays a crucial role in regulating coagulation.
    • Reduced AT III levels may be associated with thrombotic events.

    Purpose of the Study:

    • To investigate Antithrombin III (AT III) activity and concentration in patients with acute ischemic stroke.
    • To explore the relationship between AT III levels and coagulation during the acute phase and recovery.
    • To evaluate the potential benefit of AT III substitution in progressive stroke.

    Main Methods:

    • Measurement of AT III activity and concentration in 36 ischemic stroke patients within 48 hours of onset.
    • Serial measurements of AT III in 15 patients during the acute phase and at 12 months.
    • Statistical analysis to assess correlations between AT III activity and concentration over time.

    Main Results:

    • Reduced AT III activity was observed in 33% of patients during the acute phase.
    • In the acute phase, AT III activity and concentration did not correlate.
    • A significant correlation between AT III activity and concentration emerged at 12 months.
    • One patient with progressive stroke and low AT III activity showed favorable outcomes after AT III concentrate substitution.

    Conclusions:

    • Intravascular coagulation is increased during acute ischemic stroke, leading to decreased active AT III.
    • AT III levels normalize over time, with activity and concentration correlating later.
    • AT III concentrate substitution may be beneficial in managing progressive ischemic stroke with low AT III activity.

    Related Experiment Videos